Cerus Corporation 2016 Form 10-K Summary
Business context and reporting period
Cerus Corporation is a biomedical products company focused on the INTERCEPT Blood System, designed to reduce pathogens in donated blood components. The platelet and plasma systems were commercialized in the United States and selected international markets; the red blood cell system remained in development. The filing covers the fiscal year ended December 31, 2016, with quarterly data provided for the fourth quarter ended December 31, 2016.
Key 2016 initiatives included continued U.S. commercialization, development of additional platelet and plasma configurations, ongoing European red blood cell clinical programs, and execution of a five-year BARDA agreement supporting development and implementation of pathogen-reduction technology.
Financial results and key metrics
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Product revenue | $37.2 million | $34.2 million | +9% |
| Government contracts revenue | $2.1 million | — | New in 2016 |
| Total revenue | $39.3 million | $34.2 million | +15% |
| Gross profit on product revenue | $16.9 million | $10.8 million | +57% |
| Product gross margin | 45% | 31% | +14 percentage points |
| Research and development expense | $31.3 million | $25.6 million | +22% |
| SG&A expense | $48.8 million | $46.0 million | +6% |
| Loss from operations | $(61.4) million | $(61.1) million | Higher loss |
| Net loss | $(62.9) million | $(55.9) million | Higher loss |
| Basic and diluted loss per share | $(0.62) | $(0.58) basic; $(0.61) diluted | Worsened |
| Net cash used in operating activities | $(53.5) million | $(51.1) million | Higher use |
Fourth-quarter 2016 product revenue was $10.1 million, gross profit was $4.5 million, government contracts revenue was $1.8 million, and net loss was $13.5 million, or $0.13 per basic and diluted share.
At December 31, 2016, cash and cash equivalents were $22.6 million, short-term investments were $45.1 million, and the investment in Aduro marketable equity securities was $4.0 million. Total cash, cash equivalents, short-term investments, and marketable equity securities were $71.6 million, compared with $107.9 million at year-end 2015. Working capital was $67.2 million, versus $108.5 million in 2015.
Total debt had a net carrying value of $19.4 million, including $6.9 million classified as current and $12.4 million as non-current. The Oxford Finance term loans bear interest rates of 6.95% and 7.01% and mature June 1, 2019. The company was in compliance with its debt covenants at year-end.
Net cash used in investing activities was $19.9 million, while net cash provided by financing activities was $24.6 million. Cerus sold 3.5 million shares under its Cantor at-the-market agreement for $22.0 million of net proceeds. Approximately $62.3 million remained available under that agreement at year-end.
Material changes versus the prior comparable period
- Product revenue increased $3.0 million, driven primarily by higher illuminator sales in the United States and increased disposable kit volumes in European and Middle Eastern markets.
- Gross margin improved substantially, mainly because Fenwal royalties were eliminated after June 30, 2015, obsolete and manufacturing charges declined, illuminator sales increased, and inventory management improved.
- Government contracts revenue increased to $2.1 million, reflecting activity under the BARDA agreement; no such revenue was recorded in 2015.
- Research and development spending increased $5.7 million, largely because of red blood cell development, platelet and plasma PMA supplement work, and initial BARDA activities.
- SG&A increased $2.8 million due to U.S. commercialization and BARDA-related corporate activities.
- Net loss increased by $7.0 million. The prior year included a $3.6 million non-cash gain from warrant revaluation, while no such gain was recorded in 2016.
- Cash and investments declined by approximately $36.3 million, primarily reflecting operating cash use and investment activity. Operating cash use increased to $53.5 million.
- Interest expense increased to $2.4 million from $1.7 million, reflecting the higher debt balance and effective borrowing costs.
- Other comprehensive income reversed to a $7.2 million loss from a $7.3 million gain, primarily due to changes in the fair value of the Aduro investment and other available-for-sale securities.
Guidance, outlook, management commentary, risks and unusual items
Management stated that available cash, investments, expected product sales, and anticipated BARDA receipts were expected to fund requirements for at least the next twelve months. The company also stated that this assessment depended on assumptions that could prove incorrect and that additional capital could be required.
- Management expected continued operating losses until widespread adoption of INTERCEPT products is achieved, which may never occur.
- BARDA committed up to $41.6 million for the base period and exercised options, with a total potential funding opportunity of up to $185.0 million over five years. Additional funding depends on BARDA exercising options, achievement of milestones, allowable costs, audits, and continued government funding. BARDA may terminate the agreement for convenience.
- The red blood cell system was not commercialized and required additional clinical, in vitro, manufacturing, regulatory, and potentially U.S. Phase III activities. A European chronic-anemia Phase III trial was ongoing, and a CE mark submission was planned, but no regulatory approval was expected within the following twelve months.
- U.S. adoption of the platelet and plasma systems could be delayed by site-specific licenses, process validations, hospital inventory systems, reimbursement, limited product configurations, and customer evaluations.
- The company relies heavily on third-party manufacturers, including Fresenius as the primary supplier of disposable kits, and has limited qualified alternative suppliers. Supply interruptions, component obsolescence, nonconformities, or regulatory deficiencies could affect sales and margins.
- The company faces competition from pathogen-reduction technologies, pathogen testing, conventional blood products, and other blood-safety approaches. INTERCEPT does not inactivate all pathogens, including prions and certain non-enveloped viruses.
- Customer and geographic concentration remained material. Advanced Technology represented 12% of 2016 product revenue; EFS represented 23% and 25% in 2015 and 2014, respectively.
- Contractual obligations totaled $41.9 million, including $9.5 million of minimum purchase commitments, $5.8 million of manufacturing and development obligations, $22.8 million of debt principal and interest, $2.9 million of operating leases, and $1.0 million of other commitments.
- Unusual 2016 items included a $0.8 million realized gain on the sale of Aduro shares and a $0.2 million impairment charge related to construction-in-progress.
- The filing identifies risks related to regulatory approvals, clinical trial outcomes, product liability, reimbursement, intellectual property, foreign exchange, healthcare reform, government contract audits, cybersecurity, earthquakes, and the need for future financing.
The company reported effective disclosure controls and effective internal control over financial reporting as of December 31, 2016. Ernst & Young issued unqualified opinions on the financial statements and internal controls.
Important facts investors should verify
- Whether U.S. customer adoption and recurring disposable kit volumes accelerate sufficiently to offset continued operating cash burn.
- The remaining cash runway after considering the $53.5 million 2016 operating cash outflow, scheduled debt payments, inventory needs, and development spending.
- Actual BARDA option exercises, reimbursable costs, audit outcomes, milestone performance, and the timing and availability of future funding.
- Progress, safety results, regulatory submissions, and approval prospects for the red blood cell system, including the ongoing chronic-anemia trial and planned U.S. studies.
- Renewal and terms of critical supplier agreements, particularly Fresenius, Porex, NOVA, and Ash Stevens, and the availability of qualified alternative suppliers.
- The effect of reimbursement policies, FDA site-specific licensing, product-label limitations, and additional platelet configurations on the addressable U.S. market.
- Potential dilution from the remaining $62.3 million capacity under the Cantor at-the-market agreement and outstanding equity awards.
- The effect of customer concentration, distributor performance, foreign exchange movements, and market conditions in Europe, the CIS, and the Middle East.